Outpatient secondary care pathways for head and neck cancer referral result in patient delays for cancer treatment.


Journal

Annals of the Royal College of Surgeons of England
ISSN: 1478-7083
Titre abrégé: Ann R Coll Surg Engl
Pays: England
ID NLM: 7506860

Informations de publication

Date de publication:
Apr 2023
Historique:
pmc-release: 01 04 2024
medline: 4 4 2023
pubmed: 20 10 2022
entrez: 19 10 2022
Statut: ppublish

Résumé

The majority of head and neck cancer referrals are received through primary care. A proportion of cancer referrals are received through secondary care specialties. Local delivery plan (LDP) targets in Scotland for cancer investigation are set at 31 days for diagnosis and 62 days to start treatment. The aim was to audit referrals made through non-primary care pathways compared with the standard primary care pathways against LDP targets. New head and neck cancer patients between 1 January 2014 and 1 January 2019 were included. Pathway points were recorded between referral to outpatient clinic, time to multidisciplinary team discussion (MDT) and finally MDT to treatment. 1,276 new patient referrals were received over a 5-year period. Of these, 136 (10%) were referred via non-primary care pathways. The mean time for urgent suspicion of cancer (USoC) referrals to start treatment was 77 days (15 days over target) and for outpatient secondary care referrals was 102 days (40 days over target) ( Patients with head and neck cancer referred from other outpatient specialties face delays commencing cancer treatment and are also associated with a greater likelihood of being treated with palliative intent.

Identifiants

pubmed: 36260287
doi: 10.1308/rcsann.2022.0111
pmc: PMC10066648
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

352-356

Références

BMJ Qual Improv Rep. 2016 Apr 07;5(1):
pubmed: 27158494
Radiother Oncol. 2007 Jul;84(1):5-10
pubmed: 17493700
Otolaryngol Head Neck Surg. 2020 Apr;162(4):446-457
pubmed: 32093572
J Laryngol Otol. 2018 May;132(5):434-438
pubmed: 29708086
Br J Cancer. 2013 Oct 15;109(8):2027-34
pubmed: 24045658
Support Care Cancer. 2013 Aug;21(8):2237-45
pubmed: 23508893
BMC Health Serv Res. 2015 Aug 29;15:353
pubmed: 26318734
J Laryngol Otol. 2016 Jun;130(6):571-4
pubmed: 27112730
Clin Otolaryngol. 2018 Jun;43(3):861-867
pubmed: 29380938

Auteurs

P D Chakravarty (PD)

NHS Greater Glasgow and Clyde, UK.

T Ton (T)

NHS Greater Glasgow and Clyde, UK.

A Scott (A)

NHS Grampian, UK.

C Doherty (C)

NHS Greater Glasgow and Clyde, UK.

C M Douglas (CM)

NHS Greater Glasgow and Clyde, UK.

J Montgomery (J)

NHS Greater Glasgow and Clyde, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH